Compare Gilead Sciences, Inc. (GILD) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Ryanair Holdings plc — how do they compare? Gilead Sciences, Inc. trades at $135 (market cap $164.99B), while Ryanair Holdings plc trades at $60.24 (market cap $29.86B). The key difference: Gilead Sciences, Inc. is far larger — about 5.5× Ryanair Holdings plc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.47%). Which is the better fit depends on your goals.
| GILD | RYAAY | |
|---|---|---|
Market Cap | $164.99B | $29.86B |
Sector | Health | Industrials |
52-Week High | $155.80 | $73.82 |
52-Week Low | $110.56 | $53.24 |
Enterprise Value | $188.06B | $26.83B |
Dividend Yield | 2.47% | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
RYAAY trades at $60.19, down 0.59% on the day, with a neutral technical signal and bearish moving averages. The company reported mixed quarterly earnings, missing in Q4 2025 and Q2 2026 but beating in Q1 2026. Fundamentals show strong profitability with a 12.13% net margin and 22.41% ROE, supported by $13.95B revenue in 2025. Analyst sentiment is positive with a 62.5% buy rating, though recent news highlights pressure from lower fares and higher fuel costs.
The outlook for RYAAY is cautiously optimistic, with potential upside from industry consolidation and a strong balance sheet, but near-term risks include volatile fuel prices, competitive pricing pressure, and geopolitical tensions affecting travel demand. The stock's valuation at a P/E of 14.56 appears reasonable if earnings stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
